Summary:
Arizona Research Center is conducting a randomized, double-blind, multi-dose, placebo-controlled phase 2/3 study to evaluate the efficacy and safety of Fasinumab in patients with moderate to severe chronic low back pain.
Qualified Participants Must:
• Be 35 years of age or older
•
Suffer with moderate to severe chronic lower back pain for at least 3 months
•
Be taking medication currently for back pain
•
Have treatment failure with medications for back pain
*more inclusion criteria apply